Director, Commercial Analytics and Performance Reporting

Director, Commercial Analytics And Performance Reporting

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.

At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.

As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.

To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.

Essential Job Functions

The Director of Commercial Analytics and Performance Reporting will play an integral role in the successful launch of Kura Oncology's lead program. This role will lead our Commercial Analytics activities, leveraging data to drive robust analytical insights that inform our most critical business questions. S / he will work with cross-functional partners to identify and prioritize business questions, develop appropriate analytical approaches and frameworks, and generate insights to maximize commercial opportunities. This role is dynamic, fast-paced, highly collaborative, and will require a demonstrated ability to communicate intricate data concepts and drive action among a diverse group of stakeholders through compelling presentations and dashboards.

Key Responsibilities :

• Development and implementation of best-in-class strategies to align advanced analytics and data science initiatives with overall business goals
• Act as strategic partner to frame, investigate, and answer key business questions related to performance reporting, including executive reporting and interactions with senior commercial leaders.
• Develop and execute creation of in-house insights-ready reports and dashboards to drive actionable insights from internal and secondary data sources.
• Lead the evaluation, tracking, and reporting of brand performance metrics and KPIs through compelling weekly, monthly and quarterly presentations with brand and leadership teams.
• Connect insights together to tell a compelling and persuasive story and deliver clear and actionable recommendations.
• Partner with colleagues to advance the use of data sources and reporting, including I&A, Sales & Marketing, Agency partners, Market access, RWD, etc.
• Be accountable for continuous improvement and identification / utilization of new capabilities to maximize the competitive advantages of the business
• Hands-on ability to leverage diverse datasets to identify insights that inform marketing and sales strategies, shape the customer experience, and elevate impact of omnichannel programs.
• Oversee data quality management process for assigned brand / s with external and internal data providers to ensure timely, accurate and complete patient and specialty pharmacy data. Act as a key "go-to person" for resolving field reporting and data inquiries issues.
• Expertise in leading vendors / offshore data partners on connecting, integrating, and synthesizing analysis into a meaningful 'so what' recommendation
• Proven ability to act as a strategic partner with the capacity to quickly establish relationships of trust, credibility, and be seen as a partner
• Ability to identify, prioritize and describe relevant caveats and uncertainties in data, including how they relate to the business question and broader strategic priorities.
• Provide thought partnership in building and standardizing commercial reporting.

Job Specifications

The base range for a Director is $226,000 - $260,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.

Kura's Values

The Kura Package

Kura Oncology is a clinical-stage biopharmaceutical company focused on realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration ("FDA") for the treatment of relapsed / refractory ("R / R") NPM1 -mutant acute myeloid leukemia ("AML"). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R / R NPM1 -mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA's acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R / R NPM1 -mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R / R NPM1 -mutant and KMT2A -rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1 / 2 trial in combination with alpelisib for patients with PIK3CA -dependent head and neck squamous cell carcinoma.

Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender